Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). - GPS

Study identifier:D5161R00037

ClinicalTrials.gov identifier:NCT05219162

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Gene Profile in EGFRm Locally Advanced or Metastatic NSCLC patients post Osimertinib 1L treatment failure: A real-world, multi-center Study (GPS)

Medical condition

advanced NSCLC

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

182

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 25 Feb 2022
Primary Completion Date: 09 May 2024
Study Completion Date: 09 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Diagnostic

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria